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The effect of glutamine dipeptide (GDP) supplementation in patients with diabetic foot syndrome 
was evaluated. A total of 22 patients took part in the study. GDP was supplied in 10 g sachets, and 
was dissolved in water immediately before use, with ingestion once a day, after lunch or after dinner 
(20 g/day) over a period of 30 days. Quantification of foot insensitive areas, oxidative stress, blood 
cytokines, and biochemical, hematological and toxicological parameters was performed before and after 
GDP supplementation. We observed an increase in blood levels of interferon-α (P=0.023), interferon-γ 
(P=0.038), interleukin-4 (P=0.003), interleukin-6 (P=0.0025), interleukin-7 (P=0.028), interleukin-12 
p40 (P=0.017), interleukin-13 (P=0.001), leukocytes (P=0.037), eosinophils (P=0.049), and typical 
lymphocytes (P<0.001) due to GDP administration. In addition, we observed a reduced number (P=0.048) 
of insensitive areas on the foot, and reduction (P=0.047) of fasting hyperglycemia. Patients also showed 
increased blood high density lipoprotein (P<0.01) and protein thiol groups (P=0.004). These favorable 
results were associated with the absence of renal and hepatic toxicity. These results are of clinical 
relevance, since supplementation with GDP over 30 days improved clinical responses in patients with 
diabetic foot syndrome. 
Uniterms: Type 2 diabetes mellitus/treatment/study. Glutamine/effects. Nutraceuticals.
INTRODUCTION
Diabetic foot syndrome has been defined as a 
pathological condition in which peripheral vascular 
disease, peripheral neuropathy, and infection lead to 
tissue destruction, resulting in possible lower-extremity 
amputation in people with diabetes (Canavan et al., 2008).
Nerve damage in feet is characterized by increased 
oxidative stress, which leads to loss of neurons by apoptosis 
thereby reducing the regenerative capacity (Vicent et al., 
2004), associated with loss of foot sensitivity. Diabetic foot 
ulcers are very common in diabetic patients and may lead 
to amputation (Schirmer, Ritter, Fansa, 2013). Moreover, 
following amputation, 45% of patients with neuropathic 
ulcers and 55% of patients with ischemic ulcers die within 
5 years (Armstrong, Wrobel, Robbins, 2007).
The amino acid glutamine is involved in many 
processes that are vital to cell function. The molecular 
mechanisms of glutamine action remain to be elucidated 
but may involve changes in gene and protein expression, 
protein activity, and changes in oxidative status 
(Newsholme et al., 2003). For this reason, the enteral 
and parenteral administration of glutamine has been 
recommended for critically ill patients (Newsholme et 
al., 2011; Vasconcelos, Tirapegui, 2002). In addition, 
oral glutamine has been used by healthy individuals, in 
particular by athletes, to maintain immune function (Cury-
Boaventura et al., 2008). Moreover, it has been reported 
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that glutamine supplementation caused a reduction in 
systolic blood pressure, hyperglycemia, abdominal 
circumference (Mansour et al., 2015), and improved 
insulin secretion (Samocha-Bonet et al., 2015). 
Although oral glutamine treatment is beneficial for 
human health, its low solubility and stability in aqueous 
solutions limits its availability in the blood. Furthermore, 
about 50% of orally administered glutamine is extracted by 
the splanchnic bed in healthy humans (Matthews, Marano, 
Campbell, 1993). However, this problem can be overcome 
with highly soluble stable L-alanyl-L-glutamine, a 
synthetic dipeptide composed of alanine and glutamine 
(Minguette-Camara et al., 2014; Rogero et al., 2002) 
which is commonly known as glutamine dipeptide (GDP).
Thus, based on the therapeutic potential of GDP, 
we evaluated the impact of supplementation with this 
dipeptide on the metabolic profile, oxidative stress, 
hematological parameters and blood levels of cytokines.
In this clinical investigation we used a well-
established experimental approach in which each patient 
served as their own control (Sekhar et al., 2011; Borges-
Santos et al., 2012; Nguyen et al., 2014) eliminating the 
interference of several factors such as age, duration of 
diabetes, and gender.
PATIENTS AND METHODS 
Written consent to participate in this investigation 
was obtained from each patient and the study was 
conducted according to the ethical standards established by 
the Declaration of Helsinki and approved by Maringá State 
University Ethics Committee (COPEP - CAAE 204.758) 
and Clinical trial reg. n. DOI 10.1186/ISRCTN10878185, 
http://www.isrctn.com/.
Eligibility criteria included a diagnosis of type 
2 diabetes and a confirmed diagnosis of diabetic foot 
syndrome. Exclusion criteria were severe hypertension, 
ischemic heart disease, pregnancy, and liver diseases.
Subjects
A total of 22 patients were selected to participate in 
the study after a medical consultation at the University 
Hospital of Maringá State University.
During the consultation, patients were interviewed 
using a questionnaire to obtain information about their 
socio-demographic and disease factors (age, sex, medical 
history, educational level, marital status, duration of 
diabetes, diabetes-related disorders etc.), therapeutic 
profile, and lifestyle.
Regarding diabetes, 33.3% of the patients had been 
diagnosed with diabetes at least 10 years ago, 44.4% of 
the patients had been diagnosed for 11 to 20 years ago 
and 22.2% of the patients had been diagnosed over 21 
years ago.
Most patients were female (83.3%), over 60 years of 
age (61.1%), sedentary (55.6), non-smokers (94.4%) and 
had at least 8 years of schooling (77.7%). 
The majority of patients had one or more comorbidities 
associated with diabetes, namely hypertension (83.3%), 
retinopathy (66.7%), and/or nephropathy (27.8%).
Insulin, oral antidiabetic drugs, anti-hypertensive, 
and/or lipid-lowering drugs were used by 50%, 88.9%, 
83.3% and 55.6% of patients, respectively. Regular 
insulin, NPH insulin, and regular insulin/NPH were used 
by 38.9%, 5.6%, and 5.6% of patients, respectively.
Despite the fact that most patients had a family 
history of type 2 diabetes (88.9%), the majority of patients 
showed an absence of knowledge about diabetic foot 
syndrome (55.6%).
Study Design 
After the interview, a foot examination based on 
the National Hansen’s Disease Program developed by the 
University of Baton Rouge, USA was performed. This 
diabetic foot screening is not used to diagnose peripheral 
neuropathy, but to identify those patients who have lost 
protective sensation. The foot examination uses a 5.07 
monofilament, which delivers 10 g of force to 12 locations 
on each foot, i.e., 24 points of sensation in total (Tan, 2010). 
During the physical examination, we found that 
many patients already had signs of peripheral vascular 
disease resulting from type 2 diabetes, such as intermittent 
claudication (38.9%), absence of distal pulses (44.4%), 
paresthesia (50.0%), calluses (83.3%), ungual mycosis 
(33.3%), and interdigital mycosis (22.2%). Some patients 
had already undergone surgical procedures in the lower 
limbs such as debridement (11.1%), revascularization 
(5.6%), or amputation (5.6%). 
Venous blood was collected from each patient after 
an overnight fast as previously described (Zubioli et al., 
2013). After blood collection, hematological parameters 
were measured. In addition, serum glucose, triacylglycerol, 
total cholesterol, high density lipoprotein cholesterol 
(HDL-C), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), gamma glutamyltransferase 
(gamma GT), total protein, albumin, urea, and creatinine 
were evaluated by using kits from BioSys® and analyzed 
on Vitalab SelectraE® equipment. C-reactive protein was 
evaluated by using the CardioPhase hsCRP kit (Siemens®) 
and analyzed on a Siemens® nephelometer. Moreover, 
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antioxidant activity was evaluated by means of total 
antioxidant capacity (Erel, 2004) and protein thiol groups 
(Faure, Lafond, 1995).
Serum eotaxin, interferon-α (IFN-α), interferon-γ 
(IFN-γ), interleukin-1 receptor antagonist (IL-1RA), 
interleukin-2 receptor (IL-2R), interleukin 4 (IL-4), 
interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 
(IL-8), interleukin 10 (IL-10), interleukin 12 p40 (IL-
12 p40), interleukin 13 (IL-13), interleukin 15 (IL-15), 
inducible protein 10 (IP-10), monocyte chemotactic 
protein 1 (MCP-1), monokine induced by IFN-γ (MIG), 
macrophage inflammatory protein-1α (MIP-1α), and 
regulated on activation, normal T-cell expressed and 
secreted (RANTES) were quantified using the human 
cytokine magnetic plex panel produced by Invitrogen™ by 
means of the immunoassay Luminex - Magpix® platform.
Levels of erythrocytes, hemoglobin, hematocrit, 
platelets, leukocytes, basophils, eosinophils, immature 
neutrophils, segmented leukocytes, typical lymphocytes, 
atypical lymphocytes, and monocytes were evaluated, 
along with the amplitude of the distribution of erythrocyte 
size (ADES), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), and mean corpuscular 
hemoglobin concentration (MCHC) using BC Plus 3000 
for Mindray Hematology Analyzers.
Patients were required to ingest GDP (Ajinomoto 
North America, NC, USA) which was supplied in sachets 
(10 g), and was dissolved in water immediately before 
using, once a day, after lunch or after dinner (20 g/day), 
for 30 days. After this period of treatment, all clinical 
procedures were repeated (blood collection, biochemical 
and hematological evaluation, quantification of cytokines 
and foot examination). 
The effect of the treatment with GDP was evaluated 
by comparing each patient before (day 1) and after 
treatment (day 30). In this way, each patient served as his 
or her own control.
Statistical analysis
For statistical analysis we used the software 
R.2.10.1. Results were analyzed using the Wilcoxon test 
for comparing values before and after treatment. For 
quantitative variables, the Spearmanʼs correlation was 
used. Data were reported as the mean ± standard error 
(M ± SE). A p<0.05 level of probability was accepted as 
a statistically significant difference for all comparisons.
RESULTS AND DISCUSSION
A total of 18 patients with type 2 diabetes completed 
the study, while the remaining four patients were 
excluded because they did not take the GDP treatment as 
recommended. 
Supplementation with GDP reduced (P=0.048) the 
number of areas on the foot that lacked sensation from 
5.9 ± 1.5 to 4.1 ± 1.3. Moreover, individual evaluation 
(Table I) showed that 10 patients (55.5%) experienced 
a reduction in the number of points without sensation 
after supplementation with GDP. In agreement with these 
results, supplementation with glutamine has been shown 
to reduce the loss of neurons in the duodenum of diabetic 
rats. This effect was attributed to the neuroprotective effect 
of glutamine which prevents oxidative stress by increasing 
the availability of reduced glutathione from glutamine 
(Zanoni et al., 2011). 
Type 2 diabetic patients have been shown to have 
reduced antioxidant capacity (Kasznicki et al., 2012; 
Oliveira et al., 2014; Rani, Mynthili, 2014), and, therefore, 
the effect of oral GDP treatment on oxidative stress was 
evaluated. Treatment with GDP increased (P=0.004) 
protein free-thiol groups from 5.99 ± 0.17 nmol/mg protein 
to 6.73 ± 0.23 nmol/mg protein (M ± SE). However, the 
total antioxidant capacity remained unchanged (P=0.066), 
i.e., 0.73±0.02 µmol/mL (before supplementation) vs. 
0.74 ± 0.02 µmol/mL (after supplementation). The 
increased level of protein free thiol groups after oral 
GDP supplementation, suggests a contribution of the 
antioxidant properties of glutamine (Newsholme et al., 
2003, 2011).
It should be emphasized that partial recovery of 
sensation occurred in the presence of reduced (P=0.047) 
fasting hyperglycemia and increased (P<0.01) HDL 
after treatment with GDP. However, total cholesterol, 
TABLE I - Individual evaluations of the number of areas on the foot without sensation (NAFWS) in type 2 diabetic patients before 
supplementation (BS) and after supplementation (AS) with glutamine dipeptide. The numbers 1-18 represent each patient included 
in the study
NAFWS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
BS 16 1 11 7 2 1 16 9 16 7 4 15 1 0 0 1 0 0
AS 11 0 12 3 0 0 17 7 10 0 9 3 0 0 0 2 0 0
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triacylglycerol, total protein, and albumin remained 
unchanged (Table II).
The increased HDL-C, i.e., 2.9 mg/dL (Table II), is 
very important considering that: a) an elevation of 1 mg/
dL has been shown to reduce the risk of microvascular 
complications in type 2 diabetic patients (Toth et al., 
2012); b) patients with diabetic foot syndrome have 
a higher risk of cardiovascular disease (Pinto et al., 
2008); and c) hyperlipidemia is associated with diabetic 
neuropathy (Callaghan et al., 2012). 
The increased urea values (P<0.001) after GDP 
supplementation (Table II) confirm the increased ingestion 
of this dipeptide. 
The blood values of creatinine, AST, ALT, and 
GGT remained unaltered (Table II), suggesting the 
absence of renal and hepatic toxicity as consequence of 
supplementation with oral GDP. In agreement with these 
observations, it has been reported that glutamine (44-60 g/
day) does not cause any side effects (Bushen et al., 2004).
In agreement with previous studies (Weigelt et al., 
2009; Whitmont et al., 2013), we observed high blood levels 
of C-reactive protein (a marker of acute inflammation) 
before GDP treatment. However, C-reactive protein 
levels were not influenced by GDP treatment (Table II). 
This result could be partly explained by the fact that 
there is a simultaneous increase in the blood levels of 
pro-inflammatory (IFN-α, IFN-γ, IL-6, IL-7) and anti-
inflammatory (IL-4, IL-13, IL-12 p40) cytokines (Table III).
However, how can the synchronous increase of 
pro-inflammatory and anti-inflammatory cytokines during 
GDP supplementation be accounted for?
We suggest that the simultaneous rise of pro-
inflammatory and anti-inflammatory cytokines during 
GDP supplementation is indicative of a pro-inflammatory 
and anti-inflammatory balance. In agreement with this 
suggestion, we previously reported a concurrent increase of 
blood pro-inflammatory and anti-inflammatory cytokines 
during an oral glucose tolerance test (Bazotte et al., 2016; 
Eik Filho et al., 2016). Furthermore, other studies have 
also demonstrated activation of pro-inflammatory and anti-
inflammatory cytokines during sepsis (Mancilla-Ramírez 
et al., 1993), diabetes (Chatzigeorgiou et al., 2010), and 
infections (Ng et al., 2003).
This balance of pro-inflammatory and anti-
inflammatory cytokines could represent an important 
negative feedback mechanism, which protects the body 
from excessive inflammation and its consequences.
Regarding the involvement of cytokines, it must 
be noted that these substances show pleiotropic effects in 
modulating immune responses and chronic inflammation 
(Akdis et al., 2011; Dinarello, 2007).
In this context, the elevation (P=0.003) of IL-4 
induced by GDP supplementation (Table III) is very 
important, as IL-4 promotes activation of macrophages 
into reparative macrophages in damaged tissues (Novak, 
Koh, 2013). Moreover, IL-13, whose effects on immune 
cells are similar to those of the closely-related cytokine 
IL-4 (Novak, Koh, 2013) is also increased after oral GDP 
treatment (Table III). In addition, IFN-α and IFN-γ, which 
play a role in modulating immune responses by activating 
immune cells (Kim, 2011; Aroor et al., 2013) are increased 
(Table III) after oral treatment with GDP.
TABLE II - Biochemical and toxicological parameters (mean ± standard error) of diabetic patients before and after supplementation 
with glutamine dipeptide. Number of patients = 18
Biochemical parameters Before After P
Fasting glycemia (mg/dL) 155.6 ± 48.6 132.2 ± 50.5 0.047*
Creatinine (mg/dL) 1.3 ± 0.07 1.3 ± 0.09 0.396
Aspartate aminotransferase (U/L) 18.3 ± 1.77 24.8 ± 6.03 0.106
Alanine aminotransferase (U/L) 17.1 ± 2.45 17.3 ± 2.95 0.201
Gamma glutamyltransferase (U/L) 40.9 ± 8.61 44.4 ± 10.15 0.326
Total cholesterol (mg/dL) 190.2 ± 6.90 184.1 ± 7.63 0.289
High density lipoprotein (mg/dL) 54.3 ± 3.88 57.2 ± 3.84 <0.01*
Triacylglycerol (mg/dL) 158.0 ± 16.31 150.9 ± 15.00 0.472
Total protein (g/dL) 8.1 ± 0.08 8.1 ± 0.09 0.113
Albumin (g/dL) 4.5 ± 0.05 4.5 ± 0.05 0.777
Urea (mg/L) 43.3 ± 4.33 52.2 ± 4.39 <0.001*
C reactive protein (mg/L) 5.6 ± 2.6 6.5 ± 4.6 0.168
*Non parametric Wilcoxon test. A P value of <0.05 was considered as statistically significant.
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TABLE III - Serum cytokines levels (pg/mL) of diabetic patients before and after supplementation with glutamine dipeptide. 
N = number of patients
Cytokines N Before N After P
Eotaxin 18 118.39 ± 27.9 18 284.85 ± 28.4 0.492
IFN-α 17 22.41 ± 5.4 17 42.26 ± 6.5 0.023*
IFN-γ 15 4.52 ± 1.2 15 8.521 ± 1.2 0.038*
IL1-RA 17 168.68 ± 40.9 17 284.76 ± 40.2 0.638
IL-2R 18 75.36 ± 17.8 18 148.13 ± 16.1 0.084
IL-4 18 16.54 ± 3.9 18 35.89 ± 4.6 0.003*
IL-6 13 3.29 ± 0.9 13 5.41 ± 1.2 0.002*
IL-7 12 70.32 ± 20.3 12 156.33 ± 14.2 0.028*
IL-8 17 26.67 ± 6.5 17 47.84 ± 5.7 0.492
IL-10 16 1.37 ± 0.3 16 2.90 ± 0.4 0.286
IL-12p40 18 74.02 ± 17.4 18 253.49 ± 27.6 0.017*
IL-13 18 77.53 ± 18.3 18 239.10 ± 17.4 0.001*
IL-15 16 26.79 ± 6.7 16 49.92 ± 9.8 0.055
IP-10 18 31.13 ± 7.3 18 94.05 ± 8.8 0.184
MCP-1 18 98.50 ± 23.2 18 302.68 ± 30.9 0.113
MIG 16 40.65 ± 10.2 16 92.40 ± 13.0 0.071
MIP-1 α 16 18.11 ± 4.5 16 43.79 ± 5.4 0.105
RANTES 18 1880.4 ± 443.2 18 5148.6 ± 406.4 0.214
Interferon-α (IFN-α), interferon-γ (IFN-γ), interleukin-1 receptor antagonist (IL-1RA), interleukin-2 receptor (IL-2R), interleukin 
4 (IL-4), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin-12 p40 (IL-12p40), 
interleukin 13 (IL-13), interleukin 15 (IL-15), IFN-γ inducible protein 10 (IP-10), monocyte chemotactic protein 1 (MCP1), 
monokine induced by IFN-γ (MIG), macrophage inflammatory protein-1α (MIP-1α), regulated on activation normally T-cell 
expressed and secreted (RANTES). *Non parametric Wilcoxon test. A P value of <0.05 was considered as statistically significant.
TABLE IV - Hematological parameters of diabetic patients before and after supplementation with glutamine dipeptide (mean ± 
standard error). Number of patients = 18
Hematological parameters Before After P
Erythrocytes (mm3) 4.5 ± 0.10 4.6 ± 0.09 0.120
Hemoglobin (g/dL) 13.0 ± 0.32 12.6 ± 0.32 0.038*
Hematocrit (%) 40.9 ± 0.94 41.0 ± 0.92 0.979
ADES (%) 15.9 ± 0.25 15.7 ± 0.28 0.083
MCV (fL) 90.6 ± 1.27 89.4 ± 1.28 <0.01*
MHC (pg) 28.6 ± 0.51 27.4 ± 0.48 <0.001*
MCHC (%) 31.6 ± 0.21 30.7 ± 0.30 <0.01*
Platelets (mm3) 239889 ± 15075 254055 ± 16754 0.33
Leukocytes (mm3) 7344.4 ± 564.72 7944.4 ± 557.49 0.037*
Basophils (mm3) 38.8 ± 8.91 49.1 ± 10.16 0.311
Eosinophils (mm3) 198.2 ± 70.31 252.0 ± 73.87 0.049*
Immature neutrophils 2.8 ± 2.8 3.0 ± 3.0 0.968
Segmented leukocytes (mm3) 4395.8 ± 452.42 4395.6 ± 393.00 0.446
Typical lymphocytes (mm3) 2183.5 ± 156.93 2714.2 ± 200.55 <0.001*
Atypical lymphocytes (mm3) 1.5 ± 1.5 7.2 ± 7.17 0.444
Monocytes (mm3) 519.8 ± 49.42 523.3 ± 41.56 0.557
Amplitude of the distribution of erythrocyte size (ADES), mean corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration (MCHC). *Non parametric Wilcoxon test. A P value of <0.05 was considered 
as statistically significant.
T. Krupek, M. A. R. C. P. Silva, D. M. G. Sant´Ana, M. R. Batista, E. L. T. Shimauti, A. B. Sá-Nakanishi, J. F. Comar et al.572
Other cytokines that were shown to increase after 
oral treatment with GDP (Table III) include IL-6 (induces 
immune response, during infections, trauma, burns or 
other tissue damage), IL-7 (a hematopoietic growth 
factor secreted by stromal cells in the bone marrow and 
thymus), and IL-12 p40 (acts as an antagonist of IL-12, a 
pro-inflammatory cytokine).
In summary, the significant increases in IFN-α, 
IFN-γ, IL-4, IL-6, IL-7, IL-13, and IL-12 p40 may improve 
the immune responses after oral treatment with GDP. In 
agreement, with this proposition, as shown in Table IV, 
oral supplementation with GDP also increased the number 
of circulating leukocytes (P=0.037), eosinophils (P=0.049) 
and typical lymphocytes (P<0.001). 
Finally, decreased hemoglobin (P=0.038), MCV 
(P<0.01), MHC (P<0.001), and MCHC (P<0.01) were 
detected (Table IV). This implies that glutamine is 
important for hematopoiesis, as previously reported 
(Rogero et al., 2008).
Our results are of clinical relevance, as treatment 
with oral GDP (20 g/day) over a period of 30 days 
improved clinical responses in patients with diabetic foot 
syndrome.
ACKNOWLEDGMENTS
This study was funded by the Research Program for 
the unified health system (PPSUS) – Process 987/2013. 
REFERENCES
AKDIS, M.; BURGLER, S.; CRAMERI, R.; EIWEGGER, 
T.; FUJITA, H.; GOMEZ, E.; KLUNKER, S.; MEYER, 
N.; O’MAHONY, L.; PALOMARES, O.; RHYNER, C.; 
OUAKED, N.; SCHAFFARTZIK, A.; VAN DE VEEN, 
W.; ZELLER, S.; ZIMMERMANN, M.; AKDIS, C. A. 
Interleukins, from 1 to 37, and interferon-gamma: receptors, 
functions, and roles in diseases. J. Allergy Clin. Immun. 
v.127, n.3, p.701-21, 2011.
ARMSTRONG, D.G.; WROBEL, J.; ROBBINS, J.M. Guest 
editorial: are diabetes-related wounds and amputations 
worse than cancer? Int. Wound J., v.4, p.286-7, 2007.
AROOR, A.R.; MCKARNS, S.; DEMARCO, V.G.; JIA, G.; 
SOWERS, J.R. Maladaptive immune and inflammatory 
pathways lead to cardiovascular insulin. Metabolism., v.62, 
n.11, p.1543-52, 2013.
BAZOTTE, R.B.; DE CASTRO, R.M.A.; DA SILVA, 
M.A.R.C.P.; KRUPEK, T.; EIK FILHO, W. Blood levels 
of pro-inflammatory and anti-inflammatory cytokines in a 
patient with a flat glucose curve. Acta Diabetol., v.53, n.4, 
p.1-3, 2016.
BORGES-SANTOS, M.D.; MORETO F.; PEREIRA P.C.; 
MING-YU, Y.; BURINI R.C. Plasma glutathione of HIV⁺ 
patients responded positively and differently to dietary 
supplementation with cysteine or glutamine. Nutrition., 
v.28, n.7-8, p.753-6, 2012.
BUSHEN, O.Y.; DAVENPORT, J.A.; LIMA, A.B.; PISCITELLI, 
S.C.; UZGIRIS, A.J.; SILVA, T.M.; LEITE, R.; KOSEK, 
M.; DILLINGHAM, R.A.; GIRAO, A.; LIMA, A.A.; 
GUERRANT, R.L. Diarrhea and reduced levels of 
antiretroviral drugs: improvement with glutamine or alanyl-
glutamine in a randomized controlled trial in northeast 
Brazil. Clin. Infect. Dis., v.38, n.12, p.1764-70, 2004.
CALLAGHAN, B.C.; CHENG, H.T.; STABLES, C.L.; SMITH, 
A.L.; FELDMAN, E.L. Diabetic neuropathy: clinical 
manifestations and current treatments. Lancet Neurol., v.11, 
n.6, p.521-34, 2012.
CANAVAN, R.J.; UNWIN, N.C.; KELLY, W.F.; CONNOLLY, 
V.M. Diabetes and nondiabetes related lower extremity 
amputation incidence before and after the introduction of 
better organized diabetes foot care: continuous longitudinal 
monitoring using a standard method. Diabetes Care, v.31, 
n.3, p.459-63, 2008.
CHATZIGEORGIOU, A.; HAROKOPOS, V.; MYLONA-
KARAGIANNI,  C.;  TSOUVALAS, E.; AIDINIS, 
V.; KAMPER, E.F. The pattern of inflammatory/anti-
inflammatory cytokines and chemokines in type 1 diabetic 
patients over time. Ann. Med., v.42, n.6, p.426-38, 2010.
CURY-BOAVENTURA, M.F.; LEVADA-PIRES, A.C.; 
FOLADOR, A.; GORJAO, R.; ALBA-LOUREIRO, T.C.; 
HIRABARA, S.M.; PERES, F.P.; SILVA, P.R.; CURI, 
R.; PITHON-CURI, T.C. Effects of exercise on leukocyte 
death: prevention by hydrolyzed whey protein enriched 
with glutamine dipeptide: Eur. J. Appl. Physiol., v.103. n.3, 
p.289-94, 2008.
DINARELLO, C.A. Historical insights into cytokines. Eur. J. 
Immunol., v.37, s34-45, p.1-19, 2007.
Glutamine dipeptide supplementation improves clinical responses in patients with diabetic foot syndrome 573
EIK FILHO, W.; MARCON, S.S.; KRUPEK, T.; PREVIDELLI, 
I.T.; PEREIRA, O.C.; SILVA, M.A.R.C.P.; BAZOTTE R.B. 
Blood levels of pro-inflammatory and anti-inflammatory 
cytokines during an oral glucose tolerance test in patients 
with symptoms suggesting reactive hypoglycemia. Braz. J. 
Med. Biol. Res., v.49, p.pii:S0100-879X, 2016.
EREL, O. A novel automated direct measurement method for 
total antioxidant capacity using a new generation, more 
stable ABTS radical cation. Clin. Biochem., v.37, n.4, 
p.277-85, 2004.
FAURE, P.;  LAFOND, J.L.  Measurement of plasma 
sulfhidryl and carbonyl groups as a possible indicator 
of protein oxidation. In: FAVIER, A.E.; CADET, J.; 
KALNYANARAMAN, M.; FONTECAVE, M.; PIERRE, 
J.L. (Eds). Analysis of Free Radicals in Biological Systems. 
Boston, USA: Birkhäauser, 1995. p.238-47.
KASZNICKI, J.; KOSMALSKI, M.; SLIWINSKA, A.; 
MROWICKA, M.; STANCZYK, M.; MAJSTEREK, I.; 
DRZEWOSKI, J. Evaluation of oxidative stress markers in 
pathogenesis of diabetic neuropathy. Mol. Biol. Rep., v.39, 
n.9, p.8669-78, 2012.
KIM, H. Glutamine as an immunonutrient. Yonsei Med. J., v.52, 
n.6, p.892-7, 2011.
MANCILLA-RAMÍREZ, J. ;  RAMÍREZ-HERRERA, 
M.; PORTILLO-GÓMEZ, L.; GAITÁN-MEZA, J.; 
DINARELLO, C.A. Antagonists in neonatal sepsis. Bol. 
Med. Hosp. Infant Mex., v.50, n.9, p.691-3, 1993.
MANSOUR, A.; MOHAJERI-TEHRANI, M.R.; QORBANI, 
M.; HESHMAT, R.; LARIJANI, B.; HOSSEINI, S. Effect 
of glutamine supplementation on cardiovascular risk factors 
in patients with type 2 diabetes. Nutrition, v.31, p.119-26, 
2015.
MATTHEWS, D.E.; MARANO, M.A.; CAMPBELL, R.G. 
Splanchnic bed utilization of glutamine and glutamic acid 
in humans. Am. J. Physiol., v.264, n.6, p.848-54, 1993.
MINGUETTE-CAMARA, V.C.; MARQUES, A.C.R.; 
VILELA, V.R.; SCHIAVON, F.P.M.; BRUSCHI, M.L.; 
BAZOTTE, R.B. A comparison of the effects of oral 
glutamine dipeptide, glutamine, and alanine on blood 
amino acid availability in rats submitted to insulin-induced 
hypoglycemia. Nutrients, v.6, n.10, p.4520-30, 2014.
NEWSHOLME, P.; ABDULKADER, F.; REBELATO, E.; 
ROMANATTO, T.; PINHEIRO, C.H.; VITZEL, K.F.; 
SILVA, E.P.; BAZOTTE, R.B.; PROCOPIO, J.; CURI, 
R.; GORJAO, R.; PITHON-CURI, T.C. Amino acids and 
diabetes: implications for endocrine, metabolic and immune 
function. Front Biosci., v.16, p.315-39, 2011.
NEWSHOLME, P.; LIMA, M.M.R.; PROCOPIO, J.; PITHON-
CURI, T.C.; DOI, S.Q.; BAZOTTE, R.B.; CURI, R. 
Glutamine and glutamate as vital metabolites. Braz. J. Med. 
Biol. Res., v.36, n.2, p.153-63, 2003.
NG, P.C.; LI, K.; WONG, R.P.; CHUI, K.; WONG, E.; LI, 
G.; FOK, T.F. Pro-inflammatory and anti-inflammatory 
cytokine responses in preterm infants with systemic 
infections. Arch. Dis. Child Fetal Neonatal Ed., v.88, n.3, 
p.209-13, 2003. 
NGUYEN, D.; HSU, J.W.; JAHOOR, F.; SEKHAR, R.V. 
Effect of increasing glutathione with cysteine and glycine 
supplementation on mitochondrial fuel oxidation, insulin 
sensitivity, and body composition in older HIV-infected 
patients. J. Clin. Endocrinol. Metab., v.99, n.1, p.169-77, 
2014.
NOVAK, M.L.; KOH, T.J. Macrophage phenotypes during 
tissue repair. J. Leukoc. Biol., v.93, n.6, p.875-81, 2013. 
OLIVEIRA, A.C.P.; TEIXEIRA, C.J.; STEFANELLO, T.F.; 
CARRARA, M.A.; BAZOTTE, R.B.; SÁ-NAKANISHI, 
A.B.; COMAR, J.F.; BATISTA, M.R. Oxidative stress 
parameters as biomarkers of risk factor for diabetic foot 
among the patients with type 2 diabetes. Braz. Arch. Biol. 
Technol., v.57, n.2, p.223-27, 2014.
PINTO, A.; TUTTOLOMONDO, A.; DI RAIMONDO, D.; 
FERNANDEZ, P.; LA PLACA, S.; DI GATI, M.; LICATA, 
G. Cardiovascular risk profile and morbidity in subjects 
affected by type 2 diabetes mellitus with and without 
diabetic foot. Metabolism, v.57, n.5, p.676-82, 2008.
RANI, A.J.; MYTHILI, S.V. Study on Total Antioxidant Status 
in Relation to Oxidative Stress in Type 2 Diabetes Mellitus. 
J. Clin. Diagn. Res., v.8, n.3, p.108-10, 2014.
T. Krupek, M. A. R. C. P. Silva, D. M. G. Sant´Ana, M. R. Batista, E. L. T. Shimauti, A. B. Sá-Nakanishi, J. F. Comar et al.574
ROGERO, M.M.; TIRAPEGUI, J.; PEDROSA, R.G.; 
CASTRO, I.A.; PIRES, I.S.O.; OLIVEIRA, A.A.M.; 
SALGADO, M.M.; PINTO, A.R.; UEDA, M. Effect of 
L-glutamine and L-alanyl-L-glutamine supplementation on 
the response to delayed-type hypersensitivity test (DTH) in 
rats submitted to intense training. Rev. Bras. Ciênc. Farm., 
v.38, n.4, p.487-97, 2002. 
ROGERO, M.M.; TIRAPEGUI, J.; VINOLO, M.A.; BORGES, 
M.C.; DE CASTRO, I.A.; PIRES, I.S.; BORELLI, P. 
Dietary glutamine supplementation increases the activity 
of peritoneal macrophages and hemopoiesis in early-
weaned mice inoculated with Mycobacterium bovis bacillus 
Calmette-Guerin. J. Nutr., v.138, n.7, p.1343-8, 2008.
SAMOCHA-BONET, D.; CHISHOLM, D.J.; HOLST, J.J.; 
GREENFIELD, J.R. L-glutamine and whole protein restore 
first-phase insulin response and increase glucagon-like 
peptide-1 in type 2 diabetes patients. Nutrients, v.7, n.4, 
p.2101-8, 2015.
SCHIRMER, S.; RITTER, R.G.; FANSA, H. Vascular surgery, 
microsurgery and supramicrosurgery for treatment of 
chronic diabetic footulcers to prevent amputations. PLoS 
One, v.13, p.1-14, 2013.
SEKHAR, R.V.; PATEL, S.G.; GUTHIKONDA, A.P.; REID, 
M.; BALASUBRAMANYAM, A.; TAFFET, G.E.; 
JAHOOR, F. Deficient synthesis of glutathione underlies 
oxidative stress in aging and can be corrected by dietary 
cysteine and glycine supplementation. Am. J. Clin. Nutr., 
v.94, n.3, p.847-53, 2011.
TAN, L.S. The clinical use of the 10g monofilament and its 
limitations: a review. Diabetes Res. Clin. Pract., v.90, n.1, 
p.1-7, 2010.
TOTH, P.P.; SIMKO, R.J.; PALLI, S.R.; KOSELLECK, D.; 
QUIMBO, R.A.; CZIRAKY, M.J. The impact of serum 
lipids on risk for microangiopathy in patients with type 2 
diabetes mellitus. Cardiovasc. Diabetol., v.11, n.109, 2012.
VASCONCELOS, M.I. L; TIRAPEGUI, J. News aspects of 
nutritional support in the critically ill at intensive care unit 
(ICU). Rev. Bras. Ciênc. Farm., v.38, n.1, p. 23-32, 2002. 
VINCENT, A.M.; RUSSELL, J.W.; LOW, P.; FELDMAN, E.L. 
Oxidative stress in the pathogenesis of diabetic neuropathy. 
Endocr. Rev., v.25, n.4, p.612-28, 2004. 
WEIGELT, C.; ROSE, B.; POSCHEN, U.; ZIEGLER, D.; 
FRIESE, G.; KEMPF, K.; KOENIG, W.; MARTIN, S.; 
HERDER, C. Immune mediators in patients with acute 
diabetic foot syndrome. Diabetes Care, v.32, n.8, p.1491-
96, 2009. 
WHITMONT, K.; FULCHER, G.; REID, I.; XUE, M.; 
MCLKELVEY, K.; XIE, Y.; ABOUD, M.; WARD, C.; 
SMITH, M.M.; COOPER, A.; MARCH, L.; JACKSON, 
C.J. Low circulating protein C levels are associated with 
lower leg ulcers in patients with diabetes. Biomed. Res. Int., 
v.2013, p.719570, 2013. 
ZANONI, J.N.; TRONCHINI, E.A.; MOURE, S.A.; SOUZA, 
I.D. Effects of L-glutamine supplementation on the 
myenteric neurons from the duodenum and cecum of 
diabetic rats. Arq. Gastroenterol., v.48, n.1, p.66-71, 2011. 
ZUBIOLI, A.; SILVA, M.A.R.C.P.; TASCA, R.S.; CURI, R.; 
BAZOTTE, R.B. Pharmaceutical consultation as a tool to 
improve health outcomes for patients with type 2 diabetes. 
Braz. J. Pharm. Sci., v.49, p.85-94, 2013.
Received for publication on 10th November 2015
Accepted for publication on 06th September 2016
